Home/Pipeline/CRX200

CRX200

Solid Tumors

Pre-INDActive

Key Facts

Indication

Solid Tumors

Phase

Pre-IND

Status

Active

Company

BioEclipse Therapeutics

About BioEclipse Therapeutics

BioEclipse Therapeutics is pioneering a novel approach to treating solid tumors by combining innate and adaptive immune mechanisms within a single, engineered cell therapy. The company has two primary programs: an autologous therapy (CRX100) in Phase 1b trials and an IND-ready allogeneic, off-the-shelf therapy (CRX200). Focused on the significant unmet need in refractory solid tumors, which represent 90% of cancers, BioEclipse aims to overcome the high failure rates of current immunotherapies in this space with its potentially transformative and cost-effective platform.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed